Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Canada Generic Drugs Regulation

Canada Consults On Disclosing Names Of Generic Drug Applicants

  • News

Executive Summary

Health Canada currently does not disclose the names of the companies that have filed abbreviated new drug submissions and it wants to know what the possible impacts of doing so are.

You may also be interested in...



Australia Considers Identifying Drugs Filed For Approval

The Therapeutic Goods Administration wants to know whether, and how, it should disclose the fact that a medicine has been accepted for regulatory review. It has put several options to stakeholders, including disclosure for all medicines or only certain kinds, or keeping the current practice of “neither confirm nor deny.”

New Canadian Transparency Drive To Facilitate Better Planning For Industry

Health Canada is making its decision-making process in the pre-market phase more transparent by disclosing a wider range of information on new and generic drug applications accepted for review.

India Proposes Tiered Approach To Oversee Genome Editing

India has proposed three categories for grouping genetically edited organisms based on the complexity of modifications.

Table

View full table

Topics

Tags:
Canada Generic Drugs Regulation
UsernamePublicRestriction

Register

PS124601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By